I-Brand Institute imemezele ukubambisana kwayo okuyimpumelelo ne-Global Blood Therapeutics (GBT) ekuqambeni ukwelashwa kwabo okugunyazwe yi-EMA, i-OXBRYTA, ekhonjiswe ukwelapha i-hemolytic anemia ngenxa ye-sickle cell disease (SCD) ezigulini ezikhulile kanye nezingane ezineminyaka engu-12 ubudala nangaphezulu monotherapy noma ngokuhlanganiswa ne-hydroxycarbamide (hydroxyurea). Lokhu kulandela ukugunyazwa kwe-FDA kanye ne-Health Canada kokwelashwa ngo-2019.
“Yonke i-Brand Institute ne-Drug Safety Institute Team ihalalisela I-Global Blood Therapeutics ngokugunyaza kwe-FDA kwe-OXBRYTA,” kusho uSihlalo kanye ne-CEO ye-Brand Institute, u-James L. Dettore. "Lokhu kwelashwa okuguqulayo kunamandla okwenza umehluko omkhulu kulabo abaseYurophu abaphila nalesi sifo esicindezelayo."
I-OXBRYTA umuthi wokuqala ovunyelwe eYurophu ovimbela ngokuqondile i-sickle hemoglobin (HbS) polymerization, isisekelo samangqamuzana okugula nokubhujiswa kwamangqamuzana egazi abomvu ku-SCD. I-OXBRYTA isebenza ngokwandisa i-hemoglobin ehlobene nomoya-mpilo. Njengoba i-oksijini ye-sickle hemoglobin ingakhuli, i-OXBRYTA ivimbela i-cyle hemoglobin polymerization kanye nomphumela wokugula nokubhujiswa kwamangqamuzana abomvu egazi.
"Sikholelwa ukuthi igama lomkhiqizo we-OXBRYTA liwufanela kahle umkhiqizo," kuqhubeka uDettore. “Ngaphezu kwesijobelelo esihlotshaniswayo 'somoya-mpilo', kubhekiselwa endleleni yokwenziwa komkhiqizo, igama linezici eziningi nezimfanelo esiziphishekelayo lapho senza igama lomkhiqizo omusha wokwenza imithi."
